I don’t have a reference, but I believe so. NP recently stated that the FDA has recently recognized reduced CTC levels as a secondary endpoint. With Massimo Cristofanilli as one of the pioneers in CTCs (shares patents with RP) and knowledgeable of all the university research and FDA trials, it is great to have him as our Principal Investigator for the TNBC trial.